| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
28,730,000 |
| Market
Cap: |
4.11(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$123.36 - $213.66 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Krystal Biotech is a clinical-stage biotechnology company focused on the development of gene therapies to improve the lives of patients living with rare diseases. Co. has developed a gene delivery platform that enables off-the-shelf treatments for serious dermatology and respiratory diseases. Co.'s platform consists of a patented, engineered viral vector derived from the herpes simplex virus type 1 (HSV-1) that it has optimized for local and repeat gene transfer to epithelial cells. Co.'s main product candidate is Beremagene geperpavec (B-VEC), which is for the treatment of dystrophic epidermolysis bullosa, a rare skin disease caused by missing or mutated mutated type VII collagen protein.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
100,750 |
300,750 |
743,837 |
| Total Sell Value |
$0 |
$17,910,463 |
$54,167,061 |
$118,918,233 |
| Total People Sold |
0 |
3 |
3 |
4 |
| Total Sell Transactions |
0 |
5 |
13 |
34 |
| End Date |
2025-04-03 |
2024-12-31 |
2024-07-02 |
2023-07-03 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Krishnan Krish S |
President and CEO |
• • • |
2025-03-13 |
4 |
AS |
$175.97 |
$4,444,761 |
I/I |
(25,000) |
1,463,711 |
|
-22% |
|
| Krishnan Krish S |
President and CEO |
• • • |
2025-03-13 |
4 |
AS |
$175.83 |
$4,444,763 |
D/D |
(25,000) |
1,533,056 |
|
-22% |
|
| Krishnan Suma |
President, R&D |
• • • |
2025-03-13 |
4 |
AS |
$175.83 |
$4,444,763 |
I/I |
(25,000) |
1,533,056 |
|
-22% |
|
| Krishnan Suma |
President, R&D |
• • • |
2025-03-13 |
4 |
AS |
$175.97 |
$4,444,761 |
D/D |
(25,000) |
1,463,711 |
|
-22% |
|
| Krishnan Suma |
President, R&D |
• • • |
2025-02-28 |
4 |
D |
$179.25 |
$3,940,811 |
I/I |
(21,985) |
1,562,777 |
|
- |
|
| Krishnan Suma |
President, R&D |
• • • |
2025-02-28 |
4 |
OE |
$0.00 |
$0 |
I/I |
47,500 |
1,574,926 |
|
- |
|
| Krishnan Suma |
President, R&D |
• • • |
2025-02-28 |
4 |
D |
$179.25 |
$2,488,886 |
D/D |
(13,885) |
1,488,711 |
|
- |
|
| Krishnan Suma |
President, R&D |
• • • |
2025-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
30,000 |
1,499,125 |
|
- |
|
| Romano Kathryn |
Chief Accounting Officer |
• – – |
2025-02-28 |
4 |
D |
$179.25 |
$1,037,141 |
D/D |
(5,786) |
19,318 |
|
- |
|
| Romano Kathryn |
Chief Accounting Officer |
• – – |
2025-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,500 |
22,789 |
|
- |
|
| Krishnan Krish S |
President and CEO |
• • • |
2025-02-28 |
4 |
D |
$179.25 |
$2,488,886 |
I/I |
(13,885) |
1,491,997 |
|
- |
|
| Krishnan Krish S |
President and CEO |
• • • |
2025-02-28 |
4 |
OE |
$0.00 |
$0 |
I/I |
30,000 |
1,502,411 |
|
- |
|
| Krishnan Krish S |
President and CEO |
• • • |
2025-02-28 |
4 |
D |
$179.25 |
$3,940,811 |
D/D |
(21,985) |
1,558,056 |
|
- |
|
| Krishnan Krish S |
President and CEO |
• • • |
2025-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
47,500 |
1,570,205 |
|
- |
|
| Romano Kathryn |
Chief Accounting Officer |
• – – |
2025-02-27 |
4 |
AS |
$175.22 |
$131,415 |
D/D |
(750) |
12,604 |
|
-20% |
|
| Krishnan Suma |
President, R&D |
• • • |
2025-02-26 |
4 |
D |
$176.39 |
$832,737 |
I/I |
(4,721) |
1,558,056 |
|
- |
|
| Krishnan Suma |
President, R&D |
• • • |
2025-02-26 |
4 |
D |
$176.39 |
$579,618 |
D/D |
(3,286) |
1,472,596 |
|
- |
|
| Romano Kathryn |
Chief Accounting Officer |
• – – |
2025-02-26 |
4 |
D |
$176.39 |
$400,053 |
D/D |
(2,268) |
13,354 |
|
- |
|
| Krishnan Krish S |
President and CEO |
• • • |
2025-02-26 |
4 |
D |
$176.39 |
$579,618 |
I/I |
(3,286) |
1,488,711 |
|
- |
|
| Krishnan Krish S |
President and CEO |
• • • |
2025-02-26 |
4 |
D |
$176.39 |
$832,737 |
D/D |
(4,721) |
1,532,541 |
|
- |
|
| Krishnan Suma |
President, R&D |
• • • |
2024-12-13 |
4 |
AS |
$163.07 |
$4,120,499 |
I/I |
(25,000) |
1,537,262 |
|
4% |
|
| Krishnan Suma |
President, R&D |
• • • |
2024-12-13 |
4 |
AS |
$163.04 |
$4,119,524 |
D/D |
(25,000) |
1,475,882 |
|
4% |
|
| Krishnan Krish S |
President and CEO |
• • • |
2024-12-13 |
4 |
AS |
$163.04 |
$4,119,524 |
I/I |
(25,000) |
1,475,882 |
|
4% |
|
| Krishnan Krish S |
President and CEO |
• • • |
2024-12-13 |
4 |
AS |
$163.07 |
$4,120,499 |
D/D |
(25,000) |
1,537,262 |
|
4% |
|
| Rossi Dino A |
Director |
– • – |
2024-09-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,000 |
78,691 |
|
- |
|
169 Records found
|
|
Page 1 of 7 |
|
|
1.73 (1.22%) 
